ABIOMED (ABMD) Osake Kurssi
ABIOMED Kurssi
Liikevaihto on kasvanut 22,1 % vuodessa viimeisten 19 vuoden aikana 1,03 Mrd. USD:een. Osakekohtainen tulos on kasvanut 54,9 % vuodessa viimeisten 10 vuoden aikana. ABIOMEDn nettomarginaali on nyt 13,2 %, laskenut 18,9 %:sta muutama vuosi sitten.
ABIOMED osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
ABIOMED liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset ABIOMED -osakkeesta
The business model of ABIOMED Inc is focused on the development, production, and marketing of medical devices designed to support or replace the failing heart. ABIOMED specializes in advanced heart recovery, offering a range of products to address various cardiovascular conditions. Their flagship product, the Impella heart pump, provides temporary circulatory support to patients undergoing high-risk procedures such as percutaneous coronary intervention (PCI) and helps maintain stable hemodynamics. By consistently introducing innovative solutions for heart recovery, ABIOMED aims to improve patient outcomes and enhance the standard of care in cardiology.
ABIOMED Inc is primarily active in the medical devices industry.
The main competitors of ABIOMED Inc in the market include Medtronic, Inc., Edwards Lifesciences Corporation, and Boston Scientific Corporation.
ABIOMED Inc is a renowned medical technology company specializing in innovative heart pump devices. Founded in 1981, ABIOMED has a rich history of revolutionizing the field of mechanical circulatory support. With its flagship product, the FDA-approved Impella heart pumps, ABIOMED has transformed the treatment of patients suffering from heart failure worldwide. The company's cutting-edge technologies have significantly improved patient outcomes and survival rates. With a strong commitment to research and development, ABIOMED continues to lead the way in creating advanced solutions for cardiac care. ABIOMED Inc's dedication to excellence and patient-centric approach have made it a trusted name in the medical industry.
ABIOMED Inc, a leading medical technology company specializing in mechanical circulatory support devices, has achieved several significant milestones. The company's flagship product, the Impella heart pump, has obtained multiple regulatory approvals, including the FDA's Pre-Market Approval (PMA). ABIOMED has successfully expanded its global footprint and established a presence in Europe, Asia, and Latin America. The company has experienced exponential growth, surpassing $800 million in annual revenue. ABIOMED's commitment to innovation is demonstrated by the introduction of the world's smallest heart pump, Impella 2.5, and the Impella CP, both revolutionizing cardiac care. Through its relentless pursuit of improving patient outcomes, ABIOMED continues to play a pivotal role in advancing heart recovery and transforming the field of cardiovascular medicine.
ABIOMED Inc is primarily present in the United States.
ABIOMED Inc represents the values of innovation, excellence, and patient-centered care. The company's corporate philosophy focuses on developing advanced medical technologies to improve patient outcomes and transform healthcare. ABIOMED is committed to providing innovative solutions for heart recovery and support, such as their flagship product, the Impella heart pump system. With a dedication to clinical and economic value, ABIOMED prioritizes patient safety and quality, while driving growth and delivering shareholder value. Through continuous research, development, and collaboration, ABIOMED aims to redefine the standard of care for patients suffering from advanced heart failure.
16 analyytikkoa arvioi tällä hetkellä ABIOMED-osaketta: 6 suosittaa ostoa, 10 pitoa ja 0 myyntiä.
ABIOMED-osake (ABMD) on listattuna 6 pörssissä, muun muassa: NASDAQ (ABMD), London (0H7S.L), SIX (Zürich) (AIO.SW), Frankfurt (AIO.F), München (AIO.MU), Düsseldorf (AIO.DU).
ABIOMED Inc. is a leading company in the development, manufacturing, and marketing of medical devices for heart care. Founded in 1981 in Danvers, Massachusetts, ABIOMED specializes in the development of advanced technologies for the treatment of heart failure. They employ continuous improvement and innovation to enhance the lives of patients worldwide. The company is divided into various divisions, including research and development, marketing and sales, and manufacturing and production of products. Research and development constantly develop and improve new technologies to meet the needs of patients and market demands. Marketing and sales ensure the global sale and promotion of devices, while manufacturing and production ensure that all the company's products meet high quality standards. ABIOMED offers a range of products for heart care, with their flagship product being the Impella. Impella is a miniature pumping system used for short-term support of heart function in patients with severe heart disease. Impella works by continuously removing blood from the left ventricle of the heart and directly pumping it into the aorta. This improves heart function and ensures adequate blood supply to vital organs. The system is very small and is inserted into the heart during a minimally invasive procedure, reducing patient recovery time. In addition to the flagship product, ABIOMED also offers other devices for heart care, including the high-performance implant ECMO (extracorporeal membrane oxygenation), used for body support during heart surgery or severe lung problems. There are also other products, including heart monitors and probes used for monitoring, diagnosing, and treating patients with heart disease. ABIOMED's business model is focused on meeting the needs of patients, hospitals, and healthcare organizations worldwide. It is a research and innovation-based company that utilizes the latest developments in technology to improve patient care. Through extensive research programs and close collaboration with physicians and healthcare professionals, ABIOMED is able to find innovative solutions to complex medical problems. Additionally, the company has a strong global presence, allowing it to distribute its products internationally. In 2019, the company generated $769.4 million in revenue and had over 1,600 employees worldwide. Overall, ABIOMED offers innovative and advanced technologies for heart care that can improve the lives of patients worldwide. With a high-quality business model, strong global presence, and constant innovation, the company remains ready to meet the challenges and demands of the healthcare industry.
Liikevaihtoa ei voida laskea ABIOMED:lle tällä hetkellä.
Voittoa ei voida laskea ABIOMED:lle tällä hetkellä.
P/E-suhdetta ei voida laskea ABIOMED:lle tällä hetkellä.
P/S-suhdetta ei voida laskea ABIOMED:lle tällä hetkellä.
ABIOMED:n Eulpool-laatuscore on 7/10.
ABIOMED:n ISIN on US0036541003. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
ABIOMED:n WKN on 873886. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
ABIOMED:n ticker on ABMD. Tämä pörssinoteeraus käytetään ABIOMED-osakkeiden kauppaan pörssissä.
ABIOMED osake
ABIOMED vertaisryhmä
ABIOMED Ticker
ABIOMED FIGI
Kaikki tunnusluvut ja syvällinen analyysi ABIOMED:sta
Meidän osakeanalyysimme ABIOMED-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut ABIOMED:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: